Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China
- PMID: 35206282
- PMCID: PMC8871878
- DOI: 10.3390/ijerph19042096
Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China
Abstract
The prevalence of metabolic-associated fatty liver disease (MAFLD) is rarely reported in Beijing. The goal of this study was to estimate the prevalence and risk factors of MAFLD among Beijing adults aged ≥25 years old. A cross-sectional, community-based survey with multistage stratified cluster sampling was used. Demographic, transient elastography (TE), biochemical and blood examination information was collected in all the subjects in this study. The prevalence of MAFLD was 32.40% (23,832/73,566). Risk factors independently associated with MAFLD included male gender (OR = 1.47, 95%CI, 1.43-1.52), urban residence (OR = 1.06, 95% CI, 1.02-1.10), older age (30-39 years: OR = 1.29; 40-49 years: OR = 1.43; 50-59 years: OR = 1.09; ≥60 years: OR = 1.52) and lower education (middle school: OR = 2.03; high school: OR = 1.89; undergraduate: OR = 1.69). MAFLD was more common in females than in males after 50 years of age. Lean/normal weight MAFLD patients account for approximately 3.04% (724/23,832) of MAFLD. Compared to non-MAFLD subjects, the lean/normal MAFLD patients had a higher prevalence of hypertension and diabetes, and had a higher degree of hepatic steatosis and liver function enzymology parameters (all p < 0.001). MAFLD was highly prevalent among the general population aged ≥25 years old in Beijing. MAFLD was closely associated with male gender, older age, lower education and urban residence. Even lean/normal-weight people were under risk of MAFLD.
Keywords: metabolic-associated fatty liver disease; prevalence; risk factors; transient elastography.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.Hepatobiliary Pancreat Dis Int. 2022 Apr;21(2):154-161. doi: 10.1016/j.hbpd.2022.01.006. Epub 2022 Jan 31. Hepatobiliary Pancreat Dis Int. 2022. PMID: 35153138
-
Metabolic dysfunction-associated fatty liver disease in people living with HIV.Sci Rep. 2023 Jun 6;13(1):9158. doi: 10.1038/s41598-023-32965-y. Sci Rep. 2023. PMID: 37280241 Free PMC article.
-
Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.BMC Gastroenterol. 2021 May 10;21(1):212. doi: 10.1186/s12876-021-01782-w. BMC Gastroenterol. 2021. PMID: 33971822 Free PMC article.
-
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?Clin Mol Hepatol. 2021 Apr;27(2):257-269. doi: 10.3350/cmh.2021.0067. Epub 2021 Mar 22. Clin Mol Hepatol. 2021. PMID: 33751877 Free PMC article. Review.
-
Metabolic-associated fatty liver disease and lipoprotein metabolism.Mol Metab. 2021 Aug;50:101238. doi: 10.1016/j.molmet.2021.101238. Epub 2021 Apr 20. Mol Metab. 2021. PMID: 33892169 Free PMC article. Review.
Cited by
-
Metabolic Associated Fatty Liver Disease (MAFLD) and COVID-19 Infection: An Independent Predictor of Poor Disease Outcome?Medicina (Kaunas). 2023 Aug 8;59(8):1438. doi: 10.3390/medicina59081438. Medicina (Kaunas). 2023. PMID: 37629728 Free PMC article.
-
The Prospect of Non-Alcoholic Fatty Liver Disease in Adult Patients with Metabolic Syndrome: A Systematic Review.Cureus. 2023 Jul 16;15(7):e41959. doi: 10.7759/cureus.41959. eCollection 2023 Jul. Cureus. 2023. PMID: 37588314 Free PMC article. Review.
-
Development and validation of a nomogram for predicting metabolic-associated fatty liver disease in the Chinese physical examination population.Lipids Health Dis. 2023 Jun 29;22(1):85. doi: 10.1186/s12944-023-01850-y. Lipids Health Dis. 2023. PMID: 37386566 Free PMC article.
-
Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease.Metabolites. 2023 Feb 21;13(3):322. doi: 10.3390/metabo13030322. Metabolites. 2023. PMID: 36984762 Free PMC article. Review.
-
Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.Medicina (Kaunas). 2023 Mar 17;59(3):594. doi: 10.3390/medicina59030594. Medicina (Kaunas). 2023. PMID: 36984595 Free PMC article. Review.
References
-
- Eslam M., Newsome P.N., Sarin S.K., Anstee Q.M., Targher G., Romero-Gomez M., Zelber-Sagi S., Wong V.W.-S., Dufour J.-F., Schattenberg J.M., et al. A new definition for metabolic dysfunction-associated fatty liver disease: An inter-national expert consensus statement. J. Hepatol. 2020;73:202–209. doi: 10.1016/j.jhep.2020.03.039. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
